Pharma: Pharma has to find new growth pills as Covid booster wears off – Blue Barrows

The overall under-performance of the US business vis-a-vis other businesses is likely to continue in the absence of any fresh triggers. Improving R&D investments and increasing R&D productivity is going to be one of the major challenges for the companies in the sector.


The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.

ET Intelligence Group: With the weekly pandemic death toll reaching the lowest worldwide last week since March 2020, the World Health Organization has indicated the end of Covid-19 may be in sight.

However, going by the performance of the pharma sector on the bourses, the pandemic probably ended much before for the sector – a standout straggler on the stock market through the ‘reopening’ trade.

The ET Pharma Index is down 14% even as the

  • SAVE

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise